152 related articles for article (PubMed ID: 35247924)
1. A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors.
Choudhury AD; Higano CS; de Bono JS; Cook N; Rathkopf DE; Wisinski KB; Martin-Liberal J; Linch M; Heath EI; Baird RD; García-Carbacho J; Quintela-Fandino M; Barry ST; de Bruin EC; Colebrook S; Hawkins G; Klinowska T; Maroj B; Moorthy G; Mortimer PG; Moschetta M; Nikolaou M; Sainsbury L; Shapiro GI; Siu LL; Hansen AR
Clin Cancer Res; 2022 Jun; 28(11):2257-2269. PubMed ID: 35247924
[TBL] [Abstract][Full Text] [Related]
2. AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer: Results From a Phase Ib/II Study (KCSG ST18-20).
Suh KJ; Ryu MH; Zang DY; Bae WK; Lee HS; Oh HJ; Kang M; Kim JW; Kim BJ; Mortimer PGS; Kim HJ; Lee KW
Oncologist; 2023 Sep; 28(9):e823-e834. PubMed ID: 37036671
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.
Hancox U; Cosulich S; Hanson L; Trigwell C; Lenaghan C; Ellston R; Dry H; Crafter C; Barlaam B; Fitzek M; Smith PD; Ogilvie D; D'Cruz C; Castriotta L; Wedge SR; Ward L; Powell S; Lawson M; Davies BR; Harrington EA; Foster E; Cumberbatch M; Green S; Barry ST
Mol Cancer Ther; 2015 Jan; 14(1):48-58. PubMed ID: 25398829
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors.
Lynch JT; Polanska UM; Delpuech O; Hancox U; Trinidad AG; Michopoulos F; Lenaghan C; McEwen R; Bradford J; Polanski R; Ellston R; Avivar-Valderas A; Pilling J; Staniszewska A; Cumberbatch M; Critchlow SE; Cruzalegui F; Barry ST
Clin Cancer Res; 2017 Dec; 23(24):7584-7595. PubMed ID: 28972046
[No Abstract] [Full Text] [Related]
5. A Phase I Study of Capivasertib in Combination With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer.
Shore N; Mellado B; Shah S; Hauke R; Costin D; Adra N; Cullberg M; Teruel CF; Morris T
Clin Genitourin Cancer; 2023 Apr; 21(2):278-285. PubMed ID: 36572571
[TBL] [Abstract][Full Text] [Related]
6. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.
Danila DC; Morris MJ; de Bono JS; Ryan CJ; Denmeade SR; Smith MR; Taplin ME; Bubley GJ; Kheoh T; Haqq C; Molina A; Anand A; Koscuiszka M; Larson SM; Schwartz LH; Fleisher M; Scher HI
J Clin Oncol; 2010 Mar; 28(9):1496-501. PubMed ID: 20159814
[TBL] [Abstract][Full Text] [Related]
7. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors.
Tolcher AW; LoRusso P; Arzt J; Busman TA; Lian G; Rudersdorf NS; Vanderwal CA; Kirschbrown W; Holen KD; Rosen LS
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1025-32. PubMed ID: 26420235
[TBL] [Abstract][Full Text] [Related]
8. Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer.
Massard C; Chi KN; Castellano D; de Bono J; Gravis G; Dirix L; Machiels JP; Mita A; Mellado B; Turri S; Maier J; Csonka D; Chakravartty A; Fizazi K
Eur J Cancer; 2017 May; 76():36-44. PubMed ID: 28282611
[TBL] [Abstract][Full Text] [Related]
9. Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors.
Lynch JT; Polanska UM; Hancox U; Delpuech O; Maynard J; Trigwell C; Eberlein C; Lenaghan C; Polanski R; Avivar-Valderas A; Cumberbatch M; Klinowska T; Critchlow SE; Cruzalegui F; Barry ST
Mol Cancer Ther; 2018 Nov; 17(11):2309-2319. PubMed ID: 30097489
[TBL] [Abstract][Full Text] [Related]
10. A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide.
Petrylak DP; Vaishampayan UN; Patel KR; Higano CS; Albany C; Dawson NA; Mehlhaff BA; Quinn DI; Nordquist LT; Wagner VJ; Siegel J; Trandafir L; Sartor O
ESMO Open; 2021 Apr; 6(2):100082. PubMed ID: 33744812
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors.
Moreno V; Greil R; Yachnin J; Majem M; Wermke M; Arkenau HT; Basque JR; Nidamarthy PK; Kapoor S; Cui X; Giovannini M
Clin Ther; 2021 Jun; 43(6):1092-1111. PubMed ID: 34053700
[TBL] [Abstract][Full Text] [Related]
12. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
Tagawa ST; Posadas EM; Bruce J; Lim EA; Petrylak DP; Peng W; Kheoh T; Maul S; Smit JW; Gonzalez MD; De Porre P; Tran N; Nanus DM
Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075
[TBL] [Abstract][Full Text] [Related]
13. Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction.
Flaig TW; Plets M; Hussain MHA; Agarwal N; Mitsiades N; Deshpande HA; Vaishampayan UN; Thompson IM
JAMA Oncol; 2017 Nov; 3(11):e170231. PubMed ID: 28358937
[TBL] [Abstract][Full Text] [Related]
14. Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors.
Lim EA; Bendell JC; Falchook GS; Bauer TM; Drake CG; Choe JH; George DJ; Karlix JL; Ulahannan S; Sachsenmeier KF; Russell DL; Moorthy G; Sidders BS; Pilling EA; Chen H; Hattersley MM; Das M; Kumar R; Pouliot GP; Patel MR
Clin Cancer Res; 2022 Nov; 28(22):4871-4884. PubMed ID: 36044531
[TBL] [Abstract][Full Text] [Related]
15. The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer.
Ryan CJ; Crawford ED; Shore ND; Underwood W; Taplin ME; Londhe A; Francis PSJ; Phillips J; McGowan T; Kantoff PW
J Urol; 2018 Aug; 200(2):344-352. PubMed ID: 29630978
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study.
Suzuki H; Shin T; Fukasawa S; Hashine K; Kitani S; Ohtake N; Shibayama K; Tran N; Mundle S; Fizazi K; Matsubara N
Jpn J Clin Oncol; 2020 Jul; 50(7):810-820. PubMed ID: 32188988
[TBL] [Abstract][Full Text] [Related]
17. Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss.
Owusu-Brackett N; Zhao M; Akcakanat A; Evans KW; Yuca E; Dumbrava EI; Janku F; Meric-Bernstam F
Oncotarget; 2020 Mar; 11(11):969-981. PubMed ID: 32215185
[No Abstract] [Full Text] [Related]
18. Phase-1 study of abiraterone acetate in chemotherapy-naïve Japanese patients with castration-resistant prostate cancer.
Matsubara N; Uemura H; Fukui I; Niwakawa M; Yamaguchi A; Iizuka K; Akaza H
Cancer Sci; 2014 Oct; 105(10):1313-20. PubMed ID: 25117615
[TBL] [Abstract][Full Text] [Related]
19. Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
Smith MR; Saad F; Rathkopf DE; Mulders PFA; de Bono JS; Small EJ; Shore ND; Fizazi K; Kheoh T; Li J; De Porre P; Todd MB; Yu MK; Ryan CJ
Eur Urol; 2017 Jul; 72(1):10-13. PubMed ID: 28314611
[TBL] [Abstract][Full Text] [Related]
20. Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C.
Yoh K; Hirashima T; Saka H; Kurata T; Ohe Y; Hida T; Mellemgaard A; Verheijen RB; Ou X; Ahmed GF; Hayama M; Sugibayashi K; Oxnard GR
Target Oncol; 2021 May; 16(3):339-355. PubMed ID: 33939068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
